ArticleResearch square2026
Asymmetric dimethylarginine (ADMA) modulates frequency-dependent muscarinic antagonism of β-adrenergic regulation of rat papillary muscle contractility.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Accumulating evidence implicates the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in cardiovascular impairments. Although the detrimental cardiovascular effects of ADMA have largely been attributed to endothelial dysfunction, recent studies suggest that ADMA also directly affects cardiomyocyte function. However, the action of ADMA on myocardial contractility remains poorly understood. Here, we tested the hypothesis that continuous exposure to 10 μM exogenous ADMA alters the contractile responsiveness of rat right ventricular papillary muscles to sympathetic and parasympathetic stimulation using the β-adrenergic agonist isoproterenol (ISO, 1 μM) and the muscarinic agonist acetylcholine (ACh, 10 μM). We assessed force development, force-frequency relationship (FFR), contraction and relaxation kinetics, and post-rest potentiation (PRP). ADMA did not alter basal contractility or the force-frequency relationship but reduced force generation at high stimulation frequency. However, ADMA altered autonomic regulation of papillary muscle contraction in a frequency-dependent manner. Specifically, ADMA altered the inhibitory effect of ACh on ISO-induced positive inotropic and negative lusitropic responses, as well as on the ISO-mediated increases in the maximal velocities of contraction and relaxation. These effects were frequency dependent: ADMA attenuated the antagonistic effect of ACh on ISO responses at low stimulation frequencies but enhanced it at higher frequencies. Finally, ADMA attenuated ISO-induced potentiation of PRP while enhancing the inhibitory effect of ACh on PRP. Our findings identify a previously unrecognized mechanism by which ADMA directly modulates myocardial function through frequency- and time-dependent regulation of the interaction between β-adrenergic and muscarinic signaling, suggesting that elevated ADMA levels may contribute to abnormal ventricular contractile regulation in cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.